For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2010 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.
About CambrexCambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. We offer Active Pharmaceutical Ingredients ("APIs"), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Our development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com. CAMBREX CORPORATIONStatements of Profit and LossFor the Quarters Ended June 30, 2011 and 2010(in thousands)20112010% of% ofAmountSalesAmountSalesGross Sales
57,403Commissions, Allowances and Rebates523376Net Sales66,96157,027Other1,4211,190Net Revenues68,38258,217Cost of Goods Sold49,32573.1%40,28470.2%Gross Profit19,05728.2%17,93331.2%Operating ExpensesSelling, General and Administrative Expenses9,19113.6%8,18414.3%Research and Development Expenses2,5723.8%2,8414.9%Total Operating Expenses11,76317.4%11,02519.2%Operating Profit7,29410.8%6,90812.0%Other Expenses/(Income):Interest Expense, net6051,171Other (Income)/Expenses, net(282)14Equity in Losses of Partially-Owned Affiliate303-Income Before Income Taxes6,6689.9%5,72310.0%Provision for Income Taxes1,9112,057Income fro
|SOURCE Cambrex Corporation|
Copyright©2010 PR Newswire.
All rights reserved